Abstract:Abstract Background: Alzheimer’s disease (AD) is pathologically characterized by extracellular deposition of amyloid β peptide (Aβ), intracellular neurofibrillary tangles (composed mainly of phosphorylated tau [p-tau]) and neuroinflammation. The pathogenic role of inflammatory activation in AD has been extensively studied; however, the underlying mechanisms remain unclear. In this project, we investigated how neuronal IKKβ/NF-kB regulates AD-associated pathologies in APP- and tau-transgenic AD mice. Methods: APP- and tau-transgenic mice were cross-bred with ikbkb-floxed and nex-cre knock-in mice to generate AD models with deletion of IKKβ specifically in neurons. After assessing cognitive function with the Morris water maze test, mice were analyzed for Aβ and p-tau levels, microglial numbers, transcription of inflammatory genes, apoptosis and synaptic protein levels in the brain by histological, biochemical and molecular biology methods. To explore pathogenic mechanisms, we analyzed the activity and/or protein levels of: 1) β- and γ-secretases, 2) tau-phosphorylating (e.g., GSK3β and p38α-MAPK) and dephosphorylating enzymes (e.g., PP2A and PP2B), and 3) autophagy-related proteins (e.g., LC3B, beclin1 and SQSTM1/p62). In addition, IKKβ-knockdown and wild-type SH-SY5Y cell lines were created to verify the in vivo results.Results: In APP-transgenic mice, neuronal deficiency of IKKβ decreased Aβ load, inflammatory activation, and apoptosis in the brain, and improved cognitive function and maintenance of synaptic proteins (e.g., PSD-95). IKKβ deficiency decreased BACE1 activity and protein in the brain and cultured neuronal cells. In tau-transgenic mice, neuronal deficiency of IKKβ decreased p-tau, shifted pro- to anti-inflammatory activation and inhibited autophagy in the brain. IKKβ deficiency increased expression of PP2A catalytic subunit isoform A, an enzyme dephosphorylating cerebral p-tau. However, deficiency of IKKβ in neurons did not alter the cognitive function and even increased apoptosis in the brain.Conclusions: Deficiency of IKKβ in neurons attenuates Aβ and p-tau loads in the brains of AD mice. As possible molecular mechanisms, IKKβ deficiency decreases BACE1 activity, thereby reducing Aβ production, and increases PP2A expression, promoting p-tau dephosphorylation. However, IKKβ deficiency protects neurons only in APP-transgenic mice, but not in tau-transgenic AD mice. Further studies are needed before IKKβ/NF-kB can be targeted for AD therapies.

APPsα rescues CDK5 and GSK3β dysregulation and restores normal spine density in Tau transgenic mice

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Deficiency of IKKβ in neurons ameliorates Alzheimer’s disease pathology in APP- and tau-transgenic mice

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Deficiency of IKK in neurons ameliorates Alzheimer's disease pathology in APP- and tau-transgenic mice

Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation.

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

Enhanced Tau Pathology Via RanBP9 and Hsp90/Hsc70 Chaperone Complexes

Hippocampal Overexpression of SGK1 Ameliorates Spatial Memory, Rescues Aβ Pathology and Actin Cytoskeleton Polymerization in Middle-Aged APP/PS1 Mice.

Β-Amyloid Accumulation Enhances Microtubule Associated Protein Tau Pathology in an APPNL-G-F/MAPTP301S Mouse Model of Alzheimer’s Disease

Tau depletion in human neurons mitigates Aβ-driven toxicity

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

The pathogenic APP N-terminal Val225Ala mutation alters tau protein liquid-liquid phase separation and exacerbates synaptic damage

Therapeutic effects of a novel synthetic α-secretase

Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion

Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice

Lentivirus-Mediated Expression of Human Secreted Amyloid Precursor Protein-Alpha Promotes Long-Term Induction of Neuroprotective Genes and Pathways in a Mouse Model of Alzheimer's Disease

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease